Showing results (1991-2000 of 2,232) with videos related to
Sort By:
Pageof 224
Nature Communications|February 27, 2023
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trialJuliann Chmielecki, Tony Mok, Yi-Long Wu, et al.Journal for Immunotherapy of Cancer|June 21, 2020
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 studyLin Shen, Jun Guo, Qingyuan Zhang, et al.JTO Clinical and Research Reports|September 30, 2021
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042Aaron S Mansfield, Roy S Herbst, Gilberto de Castro, et al.Scientific Reports|October 25, 2016
Use of next generation sequence to investigate potential novel macrolide resistance mechanisms in a population of Moraxella catarrhalis isolatesYa-Li Liu, Dong-Fang Li, He-Ping Xu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.Clinical Lung Cancer|October 12, 2015
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLCYuan-Yuan Lei, Jin-Ji Yang, Xu-Chao Zhang, et al.Human Molecular Genetics|July 1, 2015
Increased neuronal PreP activity reduces Aβ accumulation, attenuates neuroinflammation and improves mitochondrial and synaptic function in Alzheimer disease's mouse modelDu Fang, Yongfu Wang, Zhihua Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2024
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung CancerDavid R Spigel, Afshin Dowlati, Yuanbin Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung CancerMartin Reck, Alexander Luft, Aleksandra Szczesna, et al.Future Oncology (London, England)|December 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistanceEgbert F Smit, Christophe Dooms, Jo Raskin, et al.Pageof 224